Mechanism of Action of Vitamin K2 (Menaquinone)
Vitamin K2 (menaquinone) serves as an essential cofactor for the enzyme γ-glutamyl carboxylase (GGCX), which catalyzes the post-translational carboxylation of glutamic acid residues to γ-carboxyglutamic acid (Gla) on vitamin K-dependent proteins, thereby activating these proteins for their biological functions in coagulation, bone metabolism, and vascular health. 1, 2, 3
The Vitamin K Cycle and Enzymatic Mechanism
Core biochemical pathway:
Vitamin K2 must be in its reduced hydroquinone form (vitamin KH2) to function as a cofactor for γ-glutamyl carboxylase 4, 5
During the carboxylation reaction, vitamin K2 is oxidized to vitamin K epoxide (K>O) 4
The enzyme vitamin K epoxide reductase (VKORC1) regenerates vitamin K from the epoxide form back through the quinone state to the active hydroquinone form, completing the cycle 4, 5
VKORC1 demonstrates equivalent enzymatic activity toward vitamin K1 and menaquinone-4 (MK-4), but exhibits much lower activity toward longer-chain menaquinones like MK-7 due to hydrophobic tail interactions with cell membranes 5
Protein Activation and Biological Effects
Coagulation proteins:
γ-glutamyl carboxylase activates hepatic coagulation factors II (prothrombin), VII, IX, and X through carboxylation, making them functionally competent for normal blood clotting 4, 1
Proteins C, S, and Z are also carboxylated but to a lesser extent 4
Extra-hepatic proteins:
Vitamin K2 activates matrix Gla protein (MGP), the most potent endogenous inhibitor of cardiovascular calcification, through carboxylation 2
Osteocalcin and other bone-related Gla proteins require vitamin K2-dependent carboxylation for proper bone metabolism 4, 3
Several studies suggest menaquinones may be more effective than phylloquinone at activating extra-hepatic vitamin K-dependent proteins 3
Anti-Inflammatory and Non-Canonical Actions
Beyond carboxylation:
Vitamin K2 demonstrates anti-inflammatory effects by suppressing NF-κB signal transduction, correlating with lower concentrations of inflammatory markers in vivo 4, 1
Newly discovered mechanisms include activation of the steroid and xenobiotic receptor (SXR) and regulation of oxidative stress, apoptosis, and autophagy in cancer cells 6
Structural Considerations for MK-7
Pharmacokinetic differences:
The longer hydrophobic tail of MK-7 (seven isoprenoid units) creates shaky binding to VKORC1 due to increased membrane interactions compared to shorter-chain menaquinones 5
Despite lower VKORC1 affinity, MK-7 exhibits superior bioavailability and tissue distribution compared to vitamin K1 and MK-4 3
High-dose MK-7 supplementation can potently reduce circulating levels of inactive (dephosphorylated uncarboxylated) MGP in patients with end-stage kidney disease 2
Clinical Implications
Critical caveat for anticoagulation: